Dietary vinegar prevents kidney stone recurrence via epigenetic regulations

EBioMedicine

Volumn 45, Issue , 2019, Pages 231-250

  Zhu, Wei ^a   Liu, Yang ^a   Lan, Yu ^a   Li, Xiaohang ^a   Luo, Lianmin ^a   Duan, Xiaolu ^a   Lei, Ming ^a   Liu, Guanzhao ^a   Yang, Zhou ^a   Mai, Xin ^a   Sun, Yan ^c   Wang, Li ^c   Lu, Suilin ^a   Ou, Lili ^a   Wu, Wenqi ^a   Mai, Zanlin ^a   Zhong, Dongliang ^a   Cai, Chao ^a   Zhao, Zhijian ^a   Zhong, Wen ^a   Liu, Yongda ^a   Sun, Yin ^a,b   Zeng, Guohua ^a   more..

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c People's Hospital of Changzhi   (China)

Author keywords

Acetate; Calcium; Citrate; Epigenetic regulation; microRNA; Nephrolithiasis; Vinegar

Indexed keywords

ACETIC ACID; ANTAGOMIR; CALCIUM; CALCIUM CHLORIDE; CALCIUM OXALATE; CITRIC ACID; CREATININE; ETHYLENE GLYCOL; HISTONE H3; MAGNESIUM; MICRORNA; MICRORNA 130A; MICRORNA 148B; MICRORNA 374B; MICRORNA 3P; MICRORNA 5P; NINGHUAFU; PHOSPHATE; POTASSIUM; SMALL INTERFERING RNA; SODIUM; UNCLASSIFIED DRUG; VINEGAR; CLAUDIN; CLAUDIN 14; COTRANSPORTER; DICARBOXYLATE TRANSPORTER; HISTONE; ORGANIC ANION TRANSPORTER; SLC13A2 PROTEIN, HUMAN;

ACETYLATION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CHLORIDE URINE LEVEL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CREATININE URINE LEVEL; CRYSTALLIZATION; DIET SUPPLEMENTATION; EPIGENETICS; FEMALE; GENETIC TRANSFECTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ION EXCHANGE CHROMATOGRAPHY; KIDNEY TUBULE CELL; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NONHUMAN; PHOSPHATE URINE LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADICAL NEPHRECTOMY; RANDOMIZED CONTROLLED TRIAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RNA EXTRACTION; RNA INTERFERENCE; SODIUM URINE LEVEL; TRANSEPITHELIAL RESISTANCE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE CHEMISTRY; URINE PH; UROLITHIASIS; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; URINE;

ACETIC ACID; ADULT; ANIMALS; CALCIUM; CALCIUM OXALATE; CLAUDINS; DICARBOXYLIC ACID TRANSPORTERS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; HISTONES; HUMANS; KIDNEY CALCULI; MALE; MICRORNAS; MIDDLE AGED; NEPHROLITHIASIS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RATS; RECURRENCE; SYMPORTERS;

EID: 85067097146     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2019.06.004     Document Type: Article

References (55)

1. Zeng, G., Mai, Z., Xia, S., Wang, Z., Zhang, K., Wang, L., et al. Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int 120:1 (2017 Jul), 109–116.
2. Scales, C.D., Smith, A.C., Hanley, J.M., Saigal, C.S., Prevalence of kidney stones in the United States. Eur Urol 62:1 (2012 Jul), 160–165.
3. Lotan, Y., Antonelli, J., Jiménez, I.B., Gharbi, H., Herring, R., Beaver, A., et al. The kidney stone and increased water intake trial in steel workers: results from a pilot study. Urolithiasis. 45:2 (2017 Apr), 177–183.
4. Fink, H.A., Wilt, T.J., Eidman, K.E., Garimella, P.S., MacDonald, R., Rutks, I.R., et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158:7 (2013 Apr 2), 535–543.
5. Wu, W., Yang, D., Tiselius, H.-G., Ou, L., Liang, Y., Zhu, H., et al. The characteristics of the stone and urine composition in Chinese stone formers: primary report of a single-center results. Urology. 83:4 (2014 Apr), 732–737.
6. Morgan, M.S.C., Pearle, M.S., Medical management of renal stones. BMJ., 2016 Mar 14, i52.
7. Assadi, F., Moghtaderi, M., Preventive kidney stones: continue medical education. Int J Prev Med, 8, 2017, 67.
8. Chung, J., Granja, I., Taylor, M.G., Mpourmpakis, G., Asplin, J.R., Rimer, J.D., Molecular modifiers reveal a mechanism of pathological crystal growth inhibition. Nature., 2016 Aug 8, 1–5.
9. Ogawa, N., Satsu, H., Watanabe, H., Fukaya, M., Tsukamoto, Y., Miyamoto, Y., et al. Acetic acid suppresses the increase in disaccharidase activity that occurs during culture of caco-2 cells. J Nutr 130:3 (2000 Mar), 507–513.
10. Lan, C., Chen, D., Liang, X., Huang, J., Zeng, T., Duan, X., et al. Integrative analysis of miRNA and mRNA expression profiles in calcium oxalate nephrolithiasis rat model. Biomed Res Int 2017 (2017), 1–9.
11. Leary, N.O., Pembroke, A., Duggan, P.F., Measuring albumin and calcium in serum in a dual test with the Hitachi 704. Clin Chem 38:7 (1992 Jul), 1342–1345.
12. Tiselius, H.-G., Medical evaluation of nephrolithiasis. Endocrinol Metab Clin North Am 31:4 (2002 Dec), 1031–1050.
13. Remmele, W., Stegner, H.E., Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathol. 8:3 (1987 May), 138–140.
14. Xiao, Y.-T., Wang, J., Lu, W., Cao, Y., Cai, W., Downregulated expression of microRNA-124 in pediatric intestinal failure patients modulates macrophages activation by inhibiting STAT3 and AChE. Cell Death Dis, 7(12), 2016 Dec, e2521.
15. PIZZOLATO, P., Histochemical recognition of calcium oxalate. J Histochem Cytochem 12:5 (1964), 333–336.
16. Hou, J., Renigunta, A., Konrad, M., Gomes, A.S., Schneeberger, E.E., Paul, D.L., et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 118:2 (2008 Feb [cited 2018 Jan 21), 619–628 Internet. Available from http://content.the-jci.org/articles/view/33970.
17. Li, G., Luo, W., Abdalla, B.A., Ouyang, H., Yu, J., Hu, F., et al. miRNA-223 upregulated by MYOD inhibits myoblast proliferation by repressing IGF2 and facilitates myoblast differentiation by inhibiting ZEB1. Cell Death Dis, 8(10), 2017 Oct, e3094.
18. Li, J., Yang, H., Li, Y., Liu, Y., Chen, S., Qi, C., et al. microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. Exp Mol Pathol 96:2 (2014 Apr), 195–199.
19. Mai, Z., Li, X., Cui, Z., Wu, W., Liu, Y., Ou, L., et al. Reference intervals for stone risk factors in 24-h urine among healthy adults of the Han population in China. Clin Chem Lab Med 56:4 (2018 28), 642–648.
20. Cai, C., Mai, Z., Deng, T., Zhao, Z., Zhu, W., Wen, Y., et al. Impact of dyslipidemia on 24-h urine composition in adults without urolithiasis. Lipids Health Dis, 17(1), 2018 Nov 6, 250.
21. Zhu, W., Mai, Z., Qin, J., Duan, X., Liu, Y., Zhao, Z., et al. Difference in 24-hour urine composition between diabetic and non-diabetic adults without nephrolithiasis. PLoS One, 11(2), 2016, e0150006.
22. Mai, Z., Li, X., Jiang, C., Liu, Y., Chen, Y., Wu, W., et al. Comparison of metabolic changes for stone risks in 24-hour urine between non- and postmenopausal women. PLoS One, 14(1), 2019, e0208893.
23. Bek-Jensen, H., Tiselius, H.G., Repeated urine analysis in patients with calcium stone disease. Eur Urol 33:3 (1998), 323–332.
24. Tiselius, H.G., Different estimates of the risk of calcium oxalate crystallization in urine. Eur Urol 9:4 (1983), 231–234.
25. Rendina, D., De Filippo, G., Zampa, G., Muscariello, R., Mossetti, G., Strazzullo, P., Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome. Nephrol Dial Transplant 26:7 (2011 Jul 1), 2256–2263.
26. Bilbault, H., Haymann, J.-P., Experimental models of renal calcium stones in rodents. World J Nephrol 5:2 (2016 Mar 6), 189–194.
27. Saha, S., Verma, R.J., Ethylene glycol induced renal toxicity in female Wistar rats. Toxicol Environ Heal Sci 5:4 (2013 Dec 1), 207–214.
28. Besenhofer, L.M., Cain, M.C., Dunning, C., McMartin, K.E., Aluminum citrate prevents renal injury from calcium oxalate crystal deposition. J Am Soc Nephrol 23:12 (2012 Dec 1), 2024–2033.
29. Ruiz-Agudo, E., Burgos-Cara, A., Ruiz-Agudo, C., Ibañez-Velasco, A., Cölfen, H., Rodriguez-Navarro, C., A non-classical view on calcium oxalate precipitation and the role of citrate. Nat Commun, 8(1), 2017 Oct 3, 768.
30. Worcester, E.M., Coe, F.L., Clinical practice. Calcium kidney stones N Engl J Med 363:10 (2010 Sep 2), 954–963.
31. Coe, F.L., Evan, A., Worcester, E., Kidney stone disease. J Clin Invest 115:10 (2005 Oct 1), 2598–2608.
32. Chen, D.H.-C., Kaung, H.-L.C., Miller, C.M., Resnick, M.I., Marengo, S.R., Microarray analysis of changes in renal phenotype in the ethylene glycol rat model of urolithiasis: potential and pitfalls. BJU Int 94:4 (2004 Sep), 637–650.
33. Huard, K., Brown, J., Jones, J.C., Cabral, S., Futatsugi, K., Gorgoglione, M., et al. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). Sci Rep, 5(1), 2015 Dec, 17391.
34. Ho, H.T.B., Ko, B.C.B., Cheung, A.K.H., Lam, A.K.M., Tam, S., Chung, S.K., et al. Generation and characterization of sodium-dicarboxylate cotransporter-deficient mice. Kidney Int 72:1 (2007 Jul), 63–71.
35. He, Y., Chen, X., Yu, Z., Wu, D., Lv, Y., Shi, S., et al. Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis. J Nephrol 17:1 (2004 Feb), 34–42.
36. Sayed, D., Abdellatif, M., MicroRNAs in development and disease. Physiol Rev, 2011 Jul 1 [cited 2017 Dec 7, 10.1152/physrev.00006.2010 Internet. Available from.
37. Liu, Z., Jiang, H., Yang, J., Wang, T., Ding, Y., Liu, J., et al. Analysis of altered microRNA expression profiles in the kidney tissues of ethylene glycol-induced hyperoxaluric rats. Mol Med Rep 14:5 (2016 Nov), 4650–4658.
38. Gao, X., Lin, S.-H., Ren, F., Li, J.-T., Chen, J.-J., Yao, C.-B., et al. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat Commun, 7, 2016 Jun 30, 11960.
39. 2+ transport in the thick ascending limb by regulating the tight-junction protein Claudin14. Proc Natl Acad Sci 114:16 (2017 Apr 18), E3344–E3353.
40. Gong, Y., Himmerkus, N., Plain, A., Bleich, M., Hou, J., Epigenetic regulation of MicroRNAs controlling CLDN14 expression as a mechanism for renal calcium handling. J Am Soc Nephrol 26:3 (2015 Mar 1), 663–676.
41. ++ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 31:8 (2012 Apr 18), 1999–2012.
42. Zhou, S., Wang, Y., Meng, Y., Xiao, C., Liu, Z., Brohawn, P., et al. In vivo therapeutic Success of MicroRNA-155 Antagomir in a mouse model of lupus alveolar hemorrhage: IN VIVO THERAPEUTIC SUCCESS OF miR-155 ANTAGOMIR IN PRISTANE-INDUCED DAH. Arthritis Rheum 68:4 (2016 Apr), 953–964.
43. Ma, K., He, Y., Zhang, H., Fei, Q., Niu, D., Wang, D., et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 287:8 (2012 Feb 17), 5639–5649.
44. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci 111:6 (2014 Feb 11), 2247–2252.
45. Kasubuchi, M., Hasegawa, S., Hiramatsu, T., Ichimura, A., Kimura, I., Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 7:4 (2015 Apr 14), 2839–2849.
46. Watson, A.J., Elliott, E.J., Rolston, D.D., Borodo, M.M., Farthing, M.J., Fairclough, P.D., Acetate absorption in the normal and secreting rat jejunum. Gut. 31:2 (1990 Feb), 170–174.
47. Miyamoto, J., Kasubuchi, M., Nakajima, A., Irie, J., Itoh, H., Kimura, I., The role of short-chain fatty acid on blood pressure regulation. Curr Opin Nephrol Hypertens 25:5 (2016 Sep), 379–383.
48. Andrade-Oliveira, V., Amano, M.T., Correa-Costa, M., Castoldi, A., Felizardo, R.J.F., de Almeida, D.C., et al. Gut Bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26:8 (2015 Aug 1), 1877–1888.
49. Le Poul, E., Loison, C., Struyf, S., Springael, J.-Y., Lannoy, V., Decobecq, M.-E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278:28 (2003 Jul 11), 25481–25489.
50. Coe, F.L., Evan, A., Worcester, E., Kidney stone disease. J Clin Invest 115:10 (2005 Oct), 2598–2608.
51. Sakhaee, K., Maalouf, N.M., Sinnott, B., Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97:6 (2012 Jun), 1847–1860.
52. Vasudevan, V., Samson, P., Smith, A.D., Okeke, Z., The genetic framework for development of nephrolithiasis. Asian J Urol 4(1):1 (2017 Jan), 18–26.
53. Zuckerman, J.M., Assimos, D.G., Hypocitraturia: pathophysiology and medical management. Rev Urol 11:3 (2009), 134–144.
54. Okamoto, N., Aruga, S., Matsuzaki, S., Takahashi, S., Matsushita, K., Kitamura, T., Associations between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol Off J Jpn Urol Assoc 14:4 (2007 Apr), 344–349.
55. Thorleifsson, G., Holm, H., Edvardsson, V., Walters, G.B., Styrkarsdottir, U., Gudbjartsson, D.F., et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41:8 (2009 Aug), 926–930.